Clonal Hematopoiesis in Women With Breast Cancer
Dana-Farber’s Breast Oncology Center shared an article led by Christina Mayerhofer on X about the clinical and biological data linking clonal hematopoiesis (CH) with adverse outcomes in breast cancer patients.
Clonal Hematopoiesis in Women With Breast Cancer
Authors: Christina Mayerhofer, Rachel A. Freedman, Heather A. Parsons, Ann H. Partridge, and Peter G. Miller
The article examines the role of clonal hematopoiesis (CH) in patients with breast cancer, a condition linked to adverse outcomes like hematologic malignancy and ischemic cardiovascular disease.
Recent studies suggest that CH may influence the outcomes of solid tumors, including breast cancer. This review summarizes multiple studies that assess the prevalence of CH in breast cancer patients, its relationship with cytotoxic therapy, and the correlation between CH and breast cancer-specific outcomes. The focus is particularly on clonal hematopoiesis of indeterminate potential (CHIP), a condition observed in some patients.
The findings indicate that CH is prevalent, particularly in breast cancer patients who have undergone cytotoxic treatments. However, there is no conclusive evidence supporting a direct association between CH and breast cancer outcomes.
Based on the current data, the article concludes that routine testing for CH in breast cancer patients is not recommended, and the presence of CH should not influence treatment decisions in most cases. The authors suggest that larger, long-term studies are needed to better understand the role of CH in breast cancer and guide future clinical practices.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023